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The European Union is
increasingly convinced that in
genetic testing, technology is
getting ahead of the thinking
needed to ensure appropriate
safeguards are in place before the
expected explosion in use gets
under way. With the newly
expanded EU containing 10 new
member states this month, the EU
comprises a large range of ethnic
groups which may be of interest
to genetic researchers and also a
vast difference in healthcare
systems between the richest and
poorest states over which EU-
wide guidelines or legislation may
be welcome.
Many member states, and
countries elsewhere, are grappling
with the issues, but the EU hopes
that it may be able to rise above
the particular cultural and political
issues facing individual countries.
Twelve months ago the European
Commission convened an expert
group to investigate genetic
testing, which reported earlier this
month and presented their
recommendations to a major
conference of interested parties in
Brussels.
‘At the moment, only a small
group of informed people is
familiar with the kind of decision-
making and consequences these
new technologies may infer.
Genetic testing will soon become
part of everyday healthcare
systems, and patients and
professionals will have to learn to
make decisions on the need for a
test as well as understanding its
consequences’, they say.
But the group are agreed that
genetic testing offers real
opportunities in healthcare with
the potential to lead to
developments in preventive
medicine, but that progress has
both positive and negative
implications. ‘The conditions and
context of the application of
genetic testing therefore need
assessment on a case-by-case
basis to provide maximum benefit
and minimum risk. Society needs
to ensure that genetic testing is a
matter of free choice and that it is
never imposed,’ they say.
The group are keen to
emphasise that genetic data are
no different from other medical
data. ‘Genetic information is part
of the entire spectrum of all health
information and does not
represent a separate category as
such. All medical data, including
genetic data, must be afforded
equally high standards of quality
and confidentiality at all times,’
they say.
However, the current public
perception that genetic
information is somehow different
is acknowledged by the group.
‘This perception is due to a
number of factors. These include
historical reasons as a result of
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eugenics, the current
predominance of predictive
genetic tests for rare monogenic
diseases which may give rise to
particularly sensitive information
affecting patients’ relatives, the
fact that no treatment is available
yet for most monogenic diseases,
potential loss of control over
samples, plus a number of other
reasons,’ they say.
‘As the scientific background is
complex and not always easy to
understand, it is imperative that
opportunities for education are
organized for both the public and
the media,’ they say. ‘Genetic
research and its clinical
applications should be represented
in an impartial way, and realistic
expectations as to what they can
achieve should be set.’
The EU’s efforts to reach
beyond national issues come as
concern amongst UK researchers
grows about Britain’s planned
legislation to control access to
human tissues. The bill follows on
from a highly public scandal of
organ retention from babies
without consent at two hospitals in
the UK. Researchers are worried
that the proposed legislation
makes no distinction between
tissue sample taken during
surgery and routine diagnostic
tests and the removal of organs
after death, effectively removing
any research use of such materials
without prior consent.
But the EU expert group believe
seeking consent in one form or
another is of major importance in
maintaining public trust.
‘Provision of genetic testing in the
context of human healthcare
requires appropriate procedures
for obtaining informed consent,
equitable access to testing as well
as to appropriate counselling, and
protection of confidentiality and
privacy,’ they say. ‘However, it is
imperative to recognize both the
right to know and the right not to
know as important individual
rights.’
Genetic screening for increased
disease risk will progressively
become possible for common
disorders. ‘There must be
agreement between medical
professionals, patients, and the
community that the benefits
outweigh the risks,’ the group say.
The provision of specialized
genetic counselling is considered
an essential requirement for
certain genetic tests, particularly
for highly predictive tests for
serious disorders, the group
believes.
Public concern regarding
genetic testing is grounded to
some extent in the fear of misuse
of genetic data and an
inappropriate access to such
data by third parties.
‘Confidentiality and privacy with
regard to all personal medical
data, including those derived
from genetic testing, are basic
rights, and must be respected,’
they say.
Irrespective of confidentiality
issues, personal medical data
including genetic data must not
be used to discriminate unfairly
against individuals.
‘Some genetic variants are
more common in certain
populations or groups in the EU
and elsewhere. Specific attention
should be paid to such groups in
the context of test development
and the conditions set up for the
use of these tests, both to ensure
fair access and to avoid
stigmatization or stereotyping.
Specifically, genetic tests are
inappropriate to determine
ethnicity and must never be used
for this purpose,’ they stress.
Public trust in research
surrounding genetic testing is
largely dependent on how the use
of samples and data is undertaken
and communicated. ‘This applies
in particular to the areas of
informed consent, storage, data
protection and the degree of
anonymity of samples, the
communication of study results
and, where appropriate, of
individual test results.’ The group
believe that a harmonized
approach to these issues at EU
level is desirable.
‘Genetic data represent
personal information which may
or may not have individual
medical relevance, as well as
medical or cultural relevance at
the community level,’ they say.
And they further stress again
the need for consent. ‘Biological
samples and associated or
derived genetic or medical
information of any kind and of any
origin must not be collected,
stored or used without obtaining
informed consent based on
adequate process and procedure,
including appropriate approval by
relevant review bodies, and
consideration of community-
related aspects where
appropriate, regardless of the
purpose of the collection and the
level of anonymity.’
‘Samples for genetic diversity
studies should only be obtained
in compliance with local or
national ‘traditions’ and
regulations or laws.’
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Hidden truths: What will future genetic testing reveal about our future health prospects
and how should such information best be managed and disseminated? (Photograph:
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